“We’re deploying AI where it drives measurable outcomes – helping clients optimize what works, predict what matters and automate execution to improve brand performance,” said Stephen Hoelper, Global Head, Commercial Product, Syneos Health. 

“In the HCP space, that means faster decisions, more effective engagement and stronger launch and market results,” he added.

The company stated that the AI partnerships enhance Kinetic, its commercial intelligence engine launched in 2020 to connect proprietary and partner intelligence into a continuously learning system. Syneos Health noted that Kinetic converts domain expertise into actionable insights that help strengthen HCP relationships, streamline scientific discussions and accelerate complex commercial decisions.

Kinetic is Syneos Health’s AI-powered commercial intelligence engine that combines advanced AI, behavioral intelligence and Syneos Health expertise to help biopharma organizations optimize commercial performance at scale.

Among the expanded AI partnerships, Syneos Health highlighted its collaboration with KAI Conversations, whose AI-powered conversation intelligence platform is currently used by 10 of the top 20 global pharmaceutical companies. The technology transforms interactions between field teams and HCPs into structured intelligence while also supporting individualized coaching for sales representatives, and generates aggregated brand and customer insights for commercial and medical leaders to enhance messaging and bolster HCP relationships.

In addition, the company has deployed Sageforce’s AI-powered field teams, including AI MSLs, field reimbursement managers, nurse navigators and virtual sales representatives developed by AI and neuroscience experts specifically for healthcare and life sciences. Syneos Health said this hybrid engagement approach increases reach, frequency and overall engagement impact. The company added that AI MSLs can proactively engage HCPs using approved scientific content while triaging more complex discussions to human MSLs in real time.

Further expanding its AI partnerships, Syneos Health also announced the deployment of causal AI agents through causaLens to support commercial operations. The agents are designed to assist customers in moving beyond correlation-based analysis by delivering explainable and production-ready insights in highly regulated environments like pharmaceuticals and healthcare. According to the company, the technology supports HCP targeting and scoring, engagement optimization, territory planning and continuous optimization of channel mix, media and execution.

These capabilities complement Syneos Health’s proprietary intelligence offerings, including Mindset Engine, a behavioral intelligence system built to understand HCP decision-making patterns using evidence-based behavioral drivers from nearly 14,000 HCPs across more than 30 specialties and multiple countries.

Syneos Health said the continued integration of advanced AI capabilities across its commercial suite is intended to modernize how brands launch products, engage HCPs and improve in-market performance. 

The company described the development as a major step forward for precision medicine and pharmacy operations, emphasizing that the process is no longer limited to theoretical concepts or pilot-stage testing.

The M3DIMAKER integrates pharmaceutical 3D printing, automated capsule filling, and built-in quality control into a single continuous workflow designed to improve efficiency while maintaining dosing precision. The system operated throughout the 24-hour run with minimal human intervention while preserving consistent dose control across thousands of capsules.

Traditional capsule compounding methods have long presented challenges for pharmacies due to labour-intensive preparation processes, variability in production, and difficulties associated with scaling personalized medicine. The company said those limitations are addressed through the M3DIMAKER system, where every capsule is printed and filled according to digitally defined parameters. This approach is intended to support accuracy, traceability, and reproducibility at scale while reducing operational bottlenecks tied to personalized dosing.

The company also highlighted operational benefits linked to automation within the M3DIMAKER workflow. By reducing manual handling during production, pharmacies can lower exposure to APIs while expanding personalized dosing capabilities without increasing staff workload. The automated system is also designed to free pharmacists from time-consuming compounding tasks, allowing more focus on clinical responsibilities and patient-facing care. The company described the platform as “the missing link between precision medicine and real-world pharmacy operations.”

1. Tell us more about nVentic’s proprietary analytical tools and how helpful they have been in serving the manufacturing sector.

nVentic has created a range of analytical tools that offer our manufacturing clients with insights into their inventory imbalances, thereby helping with root cause analysis and enabling a very effective decision-making. The tools, apparently, enable us to apply the most advanced statistical methodolgies to big data sets, avoiding imprecision of heuristics. This is deliberately done outside of the planning workflow itself so that our clients can pretty much gauge the sensitivities. This proactive methodology in every way enables us to rapidly go ahead and identify tangible improvement opportunities at the item level. Due to this, our clients typically experience inventory reductions which range from 20% to 50%, all while elevating or maintaining service levels. Another constant challenge with optimisation technology is the quality of master data in underlying systems. To address this concern, we have developed a range of automated data quality checks. These checks effectively pinpoint areas where data of the clients may as well need improvements, enabling them to enhance precision and also reliability of their optimization processes. Through making the rightful use of these automated checks, our clients can have much better confidence in the integrity of their data, hence leading to more accurate and also informed decision-making.

2. You are not only working with a range of clients today but are also engaged in the further development of nVentic’s tools. Can you offer some insights into it?

The fact is that inventory optimization is indeed inherently complex because of numerous variables that are in a continuous state of flux. It also depends on the operational science knowledge level that is typically limited to just a few. However, businesses are looking out for practical solutions that can easily be comprehended and used by their teams. So as to address this very issue, we are in the process of developing an intuitive user interface that allows our clients to take advantage of our advanced analytical tools without even having specialist knowledge. Our objective is to empower businesses with a very robust yet user-friendly solution that rolls out optimal results while at the same time, promoting right adoption and understanding within their organisations.

3. How does nVentic improve one’s inventory position significantly and sustainably?

We offer our clients visibility into where their biggest inventory enhancements are to be made and give them practical steps so as to attain those improvements. We help them to gauge the attributes of their different inventories and how best to go ahead and manage them.

Root cause analysis also enables in identifying the underlying issues that continuously hold inventory optimization back. Too many inventory initiatives depend on top-down pressure and the execution of a novel technology, but inventory is inherently intricate and there are no silver bullet which exist.

We help clients across all stages of inventory management maturity understand what is actually leading to their inventory imbalances and address those challenges in a systematic manner, prioritised to thrust value realisation and make it more sustainable.

By way of offering clients with these valuable insights and a systematic approach so as to address inventory challenges, we empower them to make certain informed decisions and optimize their inventory management practices in a much more effective way.

4. What is the role of artificial intelligence when it comes to inventory optimization? What efforts have been made by nVentic in this field?

Although there are a number of techniques that are pretty often referred to as AI in particular cases which call for it like multiple regression, hill-climbing and bootstrapping, we tend to rather avoid the phrase artificial intelligence, as it doesn’t really tell you what the tools are actually upto. The heart of our approach is pretty well-established and scientifically grounded approaches within the spectrum of inventory science.

There are some who use AI to find patterns in big data sets, however, compared to our approach, which is looking for very accurate traits in the data, that is an energy and time-intensive way of going about things which by the way also leaves you at the end in a catch 22 situation of the true significance of any pattern found.

Of course, exciting advances are indeed being made in the AI spectrum, and we incorporate them with all acumen where they genuinely enhance value. Nonetheless, it is necessary always to keep in mind that any sort of a tool will only be useful if it is used. Therefore, it is very pivotal that these tools are comprehensible to human users, enabling them to grasp the underlying principles and comprehending the sensitivities of the decisions being made.

Through prioritising transparency, efficiency along with human understanding, we are building inventory optimization tools that can very well empower planners to go ahead and make informed decisions, ultimately leading to elevated inventory management practices. Whether or not some of the approach is at present called AI or not is of secondary significance.

5. Tell us something about the inventory optimization algorithms that nVentic applies.

We have put together more than hundred statistical routines that go on to assess actual inventory flows, through using detailed data extracted directly from the ERP systems. We compare actual inventory levels along with the optimal inventory levels and present these deltas back to the clients along with a spectrum of insights that help them to quickly prioritise and take care of the imbalances.

While our advanced algorithms automate the processing along with the analysis of this data, it is pretty significant to note that our framework is pretty robustly rooted in inventory science that we document completely. This makes sure that the clients can always check the underlying basis, assumptions along with sensitivities that inform the overall evaluation. We prioritise transparency and also leave no stone unturned to provide our clients with an absolute understanding of the methodology, thereby helping them to have confidence in the outcomes and make well-informed decisions with regards to their inventory optimization strategies.

6. Inventory optimization holds the key to the success of a manufacturing setup today. What do you think engages the clientele since the competition is pretty tough in this domain?

Companies go on to assume that if they make the optimal strategic network decisions and have the perfect planning processes and tools, they will then they will possess exact inventories. What we in a way continuously find is that organisations put-in massive efforts into digital transformations but often go on to see little or for that matter no alterations to their inventory levels or even performance. Even where major improvements have been made, our diagnostics routinely finds that there are more double-digit improvements which are possible. Some clients choose to working with us accurately because they have hit a wall in the improvements, they can deliver themselves.

nVentic’s approach goes on to put inventories front and centre. We begin with the detailed inventory data and demonstrate clients what it tells them about supply chains. Our clients routinely make double digit enhancements to their inventory position in a matter of few months, and from there point out towards more structural challenges in a sustainable way. At the end of the day, this speed to value and deep expertise is what lets us to be the difference against some of the much bigger competition in our field.

7. Why do you believe the entire top-level executives and the team should be in sync with their inventory, as in where it stands, how fast it depletes, geography, etc.?

Inventory is indeed a strategic lever that majorly effects as well as reflects the efficiency of your working capital, the operational flexibility and the overall resilience of your business. Unfortunately, the C-suite has more often than not considered inventory as just a tactical or operational concern, which apparently is delegated to personnel many levels down the organisational hierarchy.

But the supply chain turbulence over the last few years has indeed given a wake-up call for executive boards, shedding light on strategic significance of the supply chain overall and especially, the critical role that’s been played by inventory management. This has led to better progress in terms of basic visibility. It may seem pretty steep to believe, but even for many of the biggest companies in the world, it has until recently been impossible (and for some it still is!) to even gauge what inventory you have where in anything close to real time.

At nVentic we are concentrated on taking this one step further – from what inventory you have to what inventory you really require. Here too there exists a disconnect between a board-level view, which can get mystified why so much inventory is required, and the planners at the operational level, who face multiple challenges in the day-to-day management of inventory. When these two groups are brought into sync then transformational results are indeed a possibility.

8. There are a lot of sustainability discussions taking place these days. How can inventory management in a manufacturing setup help in this regard?

Inventory management practices which are ineffective often result in the accumulation of excess inventory, thereby at the end of the day leading to obsolescence. Obsolete stock happen to represent wasted use of resources such as energy, materials, storage, maintenance along with transportation. Inventory management has in a way been neglected as a lever in sustainability, since organisations are already financially motivated so as to avoid waste. But for many organisations, especially when it comes to high-margin industries, inventory obsolescence is just seen as a cost of doing business. Nonetheless, as sustainability becomes a greater priority, inventory obsolescence should also become a greater area of focus.

9. Considering the $163 billion inventory pile-up, how can businesses help rescue the stock, and what has nVentic done in this regard?

Inventory excesses are just like an overflowing bath. The first thing to do is to go ahead and switch off the taps which in a way means quickly identifying where you have excesses and halt buying or manufacturing them. Simultaneously, efforts have to be made to deplete the present excess inventory. The worst thing to do with present excess or obsolete inventories is ignore them or in a way hope they go away. Obsolete inventory has to be regularly identified and disposed of as it incurs storage along with management costs.

At the same time, it is also necessary to assess whether excess inventory is going to naturally diminish over time or if proactive measures like active discounting, are needed so as to expedite its depletion. nVentic’s analytical tools evaluate and categorise inventories in order to enable our clients to get their inventories back under control in a much accelerated way.

10. Tell us about the real-world inventory crisis and how equipped nVentic has been in this regard.

The last few years have been a witness to many issues pertaining to supply chains. The Covid pandemic restricted movement and led to domestic production shut-downs, while the consumers stuck at home switched their spending from services to goods, thereby leading to a surge in demand. Moreover, major occurrences such as trade disputes, Ukraine war, and Brexit further aggravated the disruptions within supply chains. This put pressure on supply chain capabilities and many organisations looked out to protect themselves by raising the inventory.

The challenge is that it is frequently hard to forecast specifically which items are likely to experience shortages, so organisations do their bit to increase inventory throughout the board. For example, if a product needs 100 sub-components, shortage of just one sub-component can place the production at a standstill, despite the warehouses getting filled with increased inventories of the other 99 sub-components. This simple instance showcases why excess inventories and shortages often go together which in a way may seem to be seem paradoxical.

Over the last year, inflation, which has been majorly driven by the effect of the war in Ukraine has had on energy prices, has suppressed the demand, just when organisations are flush with inventory. nVentic has helped the clients to overcome this storm by helping with targeted inventory diagnostics – inventory optimization is not about the inventory reduction or inventory increases per se, but it is more about the understanding where you have to buffer inventories and that too by how much, and by making sure to avoid inventory excess.

Under the arrangement, healthcare organizations using Pharma Logistics for pharmaceutical returns will be able to apply accumulated credits directly toward the acquisition of Bluesight technologies. Products covered through the program include CostCheck, ControlCheck, KitCheck, ShortageCheck, 340BCheck, and PrivacyPro. The companies said the model is intended to expand pharmacy solutions access by converting recovered value from unused and expired medications into technology investments for healthcare providers. Through this structure, hospitals and health systems can fund software purchases and expansions using existing reverse distribution credits instead of waiting for traditional capital budget cycles. The partnership is also expected to provide organizations with greater flexibility in how they prioritize and deploy technology investments while enabling faster adoption of systems designed to improve compliance, operational performance, and medication management.

“Our mission has always been to empower pharmacy teams with the tools they need to operate safely and efficiently,” said Kevin MacDonald. “By partnering with Pharma Logistics, we are improving access to our critical technology. This enables health systems to turn what was once considered ‘lost’ value into a powerful engine for pharmacy innovation.”

Since late 2025, health systems across the United States have already started implementing Bluesight technologies through the credit-based model to improve visibility, strengthen compliance efforts, and support medication management operations.

David A. Hargraves said the collaboration aligns with Pharma Logistics’ broader commitment to supporting pharmacy staff through simplified return solutions. “Pharma Logistics is dedicated to providing full-service return solutions that simplify the lives of pharmacy staff,” he stated. “Our Credit Partner Program combines Pharma Logistics’ value recovery efforts with Bluesight’s industry-leading software solutions to help hospital pharmacies realize the vision of a tech-enabled future.”

The platform includes a wide range of current and planned capabilities, such as full transaction auditing across patient, provider, and location definitions, OPAIS database synchronization, contract pharmacy and pharmacy service agreement management, Medicare cost report maintenance, Medicaid exclusion file validation, policy and procedure management, mock HRSA audits, as well as integrated documentation and task management.

The launch arrives during what the company described as a difficult period for the 340B program, which has become increasingly important to the financial stability of healthcare organizations. During fiscal year 2025, HRSA audited 115 covered entities, with nearly half receiving adverse findings. Incorrect OPAIS records were identified in 75% of those audited entities, reinforcing the need for broader compliance infrastructure beyond transaction-level auditing alone. At the same time, healthcare organizations are managing evolving manufacturer data-sharing demands, ongoing discussions around rebate-based distribution models from HRSA, and changing contract pharmacy disputes occurring at the state level.

As compliance expectations continue to grow, covered entities are facing significantly greater regulatory and documentation burdens while often relying on the same operational teams they had several years ago. Many organizations are also simultaneously expanding their 340B programs, contributing to a rising number of auditable transactions.

Bluesight said the redesigned 340BCheck platform was built specifically to help covered entities remain continuously prepared for HRSA audits. According to the company, the workflows were structured around actual HRSA audit requirements, beginning with the standards necessary for a successful audit and then moving on to provide workflows designed to support continuous audit readiness.

The updated system builds on years of operational experience among 340B program teams while introducing a faster and more intuitive interface.

“340B compliance used to be about spot checks, but today it’s about continuous readiness,” noted Kevin MacDonald. “Audit scrutiny is rising, manufacturer requirements are expanding, and a potential rebate model could add entirely new documentation layers — without any increase in team size for most organizations. Covered entities should be audit-ready every single day, not just when HRSA shows up.”

The redesigned 340BCheck platform was previewed at both ASHP Midyear in December 2025 and the 340B Coalition Annual Conference in February 2026, where program managers responded positively to its emphasis on continuous compliance coverage. Bluesight also stated that it is developing additional capabilities designed for a rebate-based pricing model inside the 340B program, including tools supporting procurement decisions, aligning 340B transaction audits with rebate-eligible transactions, and rebate payment tracking.

Bluesight uses intelligence to power hospital operations, making procurement, compliance, and inventory management simpler . Bluesight guarantees that health systems safeguard every patient and maximise every dollar with its array of industry-leading technologies. Every day, more than 3,000 hospitals in the US and Canada depend on Bluesight for effective and secure operations.

At Interpack 2026 , Mettler-Toledo Product Inspection (Hall 11 Stand A60), a global leader in precision instruments and inspection solutions, will present a portfolio of proven inspection technologies, software and global service capabilities designed to support pharmaceutical manufacturers in building more precise, compliant and connected production environments.

Under the theme “Inspect. Protect. Comply.”, the company will demonstrate how product inspection solutions are evolving to support the future of smart manufacturing in pharmaceutical production, where accuracy, traceability and data integrity are critical at every stage of the process.

Building smarter pharmaceutical manufacturing through inspection capability

As pharmaceutical production becomes increasingly digitalised, product inspection plays a central role in maintaining process control, product quality and compliance.

At Interpack, Mettler-Toledo will highlight how its technologies support core inspection capabilities including weight control, physical contamination detection, integrity checks, and label inspection.

These capabilities help manufacturers inspect every product with confidence, protect product quality and patient safety, and comply more easily with regulatory requirements, forming a strong foundation for smarter, more connected pharmaceutical manufacturing.

Accurate weight control at high speeds

The C35 AdvancedLine high performance checkweigher will be showcased for pharmaceutical applications, supporting precise weight control at high throughput rates of up to 600 packs per minute. The system conducts completeness checks, and accurately detects overfills and underfills, supporting compliance with weights and measures regulations, including FDA 21 CFR Part 11 standards and helping to maintain consistent product quality.

Its ability to operate at very high speeds while maintaining measurement accuracy makes it well suited to modern pharmaceutical production lines where both performance and precision are essential.

Metal detection for pharmaceutical applications

Mettler-Toledo will showcase its Tablex-PRO metal detector, designed specifically for the enhanced inspection of pharmaceutical tablets and capsules. The ultra-high sensitivity metal detector, identifies stainless steel contaminants less than 0.3 mm in diameter and removes the contaminated product early in the production process. This integrated system is easy to use and supports compliance with pharmaceutical standards including FDA 21 CFR parts 210, 211, and 11, and GAMP 5.

By combining precise metal detection with stable and repeatable performance, the technology provides consistent inspection results in applications where even small contaminants can present a significant risk to product safety and quality. With a compact, flexible design the metal detection system can be easily installed in environments with restricted space.

Precision x-ray inspection for regulated environments

Pharmaceutical production requires consistent, repeatable inspection performance across a wide range of dosage forms and packaging formats. Mettler-Toledo will demonstrate how its x-ray inspection portfolio supports these requirements.

Systems such as the X12 perform integrity checks including completeness verification, helping manufacturers identify missing or damaged products before they reach the end user. Simultaneously, the X12 reliably detects foreign bodies in small and medium-sized pharmaceutical packages, supporting high levels of quality control in precision-driven environments.

NEW: AI-driven inspection for enhanced quality control

At Interpack, Mettler-Toledo will introduce advanced AI capabilities within its x-ray inspection systems. These technologies are designed to improve inspection accuracy in complex scenarios, such as overlapping products, mixed product types and random product positioning on the line.

AI supports integration with conventional contamination inspection tools improving inspection reliability while reducing unnecessary product rejection, contributing to more efficient and consistent production processes.

Lifecycle support through global service

Maintaining inspection performance over time is critical in pharmaceutical production, where equipment reliability, documented performance and validation are essential.

Mettler-Toledo will highlight its global service offering, supporting manufacturers throughout the full lifecycle of their inspection systems, from installation and qualification through to maintenance and performance verification. Combining global reach with local support enables fast response times, delivered by experts on-site and remote support teams.

This approach helps maintain consistent performance, reduces unplanned downtime and supports ongoing compliance with validation and regulatory requirements.

Supporting industry knowledge and best practice

In addition to its technology portfolio, Mettler-Toledo will introduce a new pharmaceutical inspection guide, providing practical insights into inspection strategies, compliance considerations and best practices for pharmaceutical production environments.

The guide reflects the company’s focus on supporting customers not only with technology, but also with the knowledge required to apply product inspection solutions effectively in highly regulated industries.
“Pharmaceutical manufacturers are operating in a highly regulated environment where precision, documentation and consistency are critical,” said Miriam Krechlok, Segment Marketing Manager at Mettler-Toledo Product Inspection. “At Interpack, we are pleased to demonstrate to visitors how our proven inspection solutions support smarter manufacturing by combining reliable detection, precision weighing and global service expertise. This helps our customers inspect every product with confidence, protect product quality and comply more easily with regulatory requirements.”

Visitors can experience live demonstrations and explore pharmaceutical product inspection systems at Interpack 2026 in Hall 11 Stand A60. For more information, click here or visit www.mt.com/pi-pr.

Sample interference is one of the most common and least discussed causes of poor results in chemiluminescent immunoassay (CLIA) Kits. It doesn’t announce itself. It just quietly ruins your data.

If you’re dealing with this right now, you are not alone. Here’s how to find it and fix it.

What Does Sample Interference Actually Look Like?

It rarely looks like a blunt failure. The signal is still there. The controls pass. But your unknowns show unexpected patterns, results that spike in one replicate and collapse in another, or values that trend in the wrong direction compared to your standard curve.

The culprit is usually something in the sample matrix that either competes with your target analyte, cross-reacts with the antibody, or quenches the chemiluminescent signal itself. Common offenders include hemoglobin, lipids, bilirubin, rheumatoid factor, and heterophilic antibodies.

Spike a known concentration of your analyte into the problematic sample matrix. If you get poor recovery (below 80% or above 120%), interference is almost certainly your problem.

My Samples Are Hemolyzed. Does That Really Affect CLIA Results?

Yes, more than most people realize. Hemoglobin and heme-containing compounds absorb light across a broad spectrum. In a Chemiluminescent Immunoassay (CLIA) test, even moderate hemolysis can reduce the signal and lead to lower results.

The fix isn’t just “don’t use hemolyzed samples.” In clinical or animal study work, that’s sometimes not an option. Instead:

Dilute the sample further into the linear range of the assay, if your analyte concentration permits.

Always include a matrix-matched blank so you can subtract background from each sample type. Use the kit’s recommended diluent instead of PBS or water to keep results consistent.

Heterophilic Antibodies Are Easy To Miss

This one trips up even experienced labs. Heterophilic antibodies, including human anti-mouse antibodies (HAMA), can bridge the capture and detection antibodies in a sandwich CLIA format. This creates a false-positive signal that has nothing to do with your analyte.

If you’re working with human serum samples and seeing anomalously high values in a sandwich format, add a heterophilic antibody blocking reagent to your diluent.

What About Lipemic Or Icteric Samples?

Lipemic (high-fat, turbid) and icteric (high-bilirubin, yellowish) samples are common preanalytical issues.  Also, they’re part of the HIL profile that the researcher uses to assess sample quality. Both can change your results if they are not handled properly, basically in light-based assays.

What’s The Issue With These Samples?

Lipemia scatters light and reduces signal accuracy, while icterus (high bilirubin) affects signal detection or disturbs the antibody-antigen binding. This can give lower results than expected.

How Do You Detect These Interferences?

Try to identify whether a sample contains excess lipids or bilirubin that could affect your results. Visual inspection can give a clue (milky for lipemia, yellow for icterus), but it’s not very reliable. If possible, use analyzer-based serum indices for a more accurate assessment.

How To Handle Lipemic Samples:

The main problem is excess lipids interfering with signal detection.

What you can do: A high-speed centrifugation step (10,000–15,000 × g for 10 minutes at 4°C) helps remove much of the lipid fraction. It won’t eliminate interference, but it typically improves signal recovery to an acceptable range.

How To Handle Icteric Samples:

The issue here is that high bilirubin affects the performance of the assay.

What you can do: Dilution is usually the simplest approach. Just make sure to run a parallelism check. Serially dilute the sample and confirm that it follows your standard curve. This ensures your results are still reliable.

A Few Things Worth Standardizing Immediately

Beyond the specific fixes above, sample interference compounds when collection and handling aren’t consistent. These three practices help across all sample types:

1. Standardize your collection tube type: EDTA plasma, heparin plasma, and serum behave differently. Heparin, in particular, can inhibit enzyme-based detection systems. Use the matrix type validated by the kit manufacturer.
2. Keep freeze-thaw cycles to a minimum: Each cycle degrades some analyte and can concentrate matrix contaminants. Aliquot samples before freezing.
3. Equilibrate samples to room temperature before use: Cold samples pulled straight from the freezer can cause condensation and microdroplet variation that looks like interference but is actually a temperature effect.

Final Thought

Sample interference is solvable. It just requires being systematic, ruling out the most common causes one at a time, rather than changing everything at once and losing track of what actually worked.

Choosing a well-validated kit is part of the equation, too.

The move to Vienna and the introduction of refreshed formats proved a resounding success, with record engagement, packed sessions and a strong pipeline of exhibitor announcements signalling continued momentum across the sector.

This year’s edition reflected a maturing conversation within pharmaceutical and biotech supply chains, grounded in practical application, resilience and real-world value. That was evident both on stage and across the exhibition floor, where suppliers showcased solutions designed to address today’s most pressing operational challenges.

The focus on interaction delivered tangible results. Delegates submitted 321 questions via the event app, underlining strong audience participation and the appetite for open, honest discussion. Sessions across both the Supply Chain and Logistics tracks benefited from live polling, audience-led debate and practical peer-to-peer exchange.

Reflecting on the themes that shaped discussions throughout the week, Ben Sharples, Event Director of LogiPharma, highlighted a noticeable shift in how the industry is approaching transformation:

“AI dominated the conversation again this year, but the tone was far more grounded. There’s a growing realism about what the technology can deliver right now, as well as where its limitations still lie.”

According to Sharples, true end‑to‑end visibility emerged as the single most critical capability for supply chains responding to major disruption. Survey data shared during sessions revealed that 50% of respondents felt AI had not helped at all during the recent Middle East crisis, reinforcing the message that technology alone is not a silver bullet.

Other key learnings included the increasing alignment between supply chain and commercial teams, with organisations placing greater emphasis on growth, market share and customer outcomes. Sharples also noted that while AI continues to attract attention, poor data quality remains the root cause of many failed initiatives, often overlooked amid the hype.

Crucially, people and culture continue to define success. “Even the best technology won’t deliver if it’s in the wrong hands,” Sharples added. “Digital transformation is still, at its core, a people and change challenge.”

With major disruption now viewed as inevitable rather than exceptional, the LogiPharma agenda reinforced the need for resilient networks and predictive capabilities. Looking ahead, AI‑enabled control towers were widely cited as a foundational element, increasingly acting as the nervous system of modern supply chains, shifting organisations from reactive recovery to proactive foresight.

Other highlights from across the conference

A larger exhibitor zone and wider variety of formats meant that the move to Vienna was also praised by sponsors.

“People love the interactive elements of LogiPharma and these extend from plenaries and round-tables, to the experiential activities brought by sponsors, including a F1 simulator and an A.I. photobooth,” confirmed Jake Brown, Commercial Lead at LogiPharma.

“Exhibitors used LogiPharma as a platform to launch and showcase next-generation technologies aimed at improving resilience, reducing risk, balancing cost and sustainability, and strengthening cold chain integrity,” he added.

TransVoyant announced the launch of Risk in Motion, a new solution designed to analyse multiple data sources against disruption threats. The platform enables supply chain teams to act ahead of potential issues, protecting shipments, inventory and temperature-sensitive products in real time.

Cold chain innovation continued with Peli BioThermal’s introduction of a new SmartCap for DV10 dewars, offering enhanced visibility and reliability for high‑value cell and gene therapy shipments.

Visitors to Woolcool were introduced to the LifeGUARDIAN® thermal box system, a fully passive packaging solution designed to protect temperature‑sensitive payloads for up to 120 hours. The system combines a layered design including an outer carton, fleece jacket, thermal core and ice packs to deliver consistent and reliable temperature control without the need for active components.

Innovation from emerging companies was also firmly in the spotlight. Tapp was named Start Up Village Champion, recognised for its progress in developing a simpler and more sustainable way to manage temperature-controlled shipments. The company was selected for its focus on reducing e‑waste and enabling instant data access without the need for additional hardware.

Beyond technology, the event also highlighted the importance of partnership and shared purpose. A standout moment was Yusen Logistics hosting a traditional Japanese Kagami Biraki sake barrel‑opening ceremony, symbolising new beginnings and strengthened collaboration.

The fundamental advantage of injectable systems is their ability to bypass the “first-pass metabolism” of the liver, ensuring that 100% of the drug enters the systemic circulation immediately. This is particularly crucial for life-saving treatments like epinephrine for anaphylaxis or insulin for diabetic crises. Beyond speed, the precision offered by injectable formulations is unmatched. In oncology and intensive care, where the difference between a therapeutic dose and a toxic one can be incredibly small, the ability to deliver a precise volume of medication directly into the bloodstream or muscle tissue is a cornerstone of patient safety. As we move further into the era of personalized and biological medicine, the role of these advanced delivery systems will only continue to grow in importance.

The Transformation of Pharma Manufacturing for Injectables

The production of injectable medications is one of the most demanding areas of pharma manufacturing. Because these drugs are delivered directly into the body’s internal environment, they must be absolutely sterile and free from pyrogens or particulate matter. The recent shift toward more complex biopharmaceuticals has required a simultaneous evolution in manufacturing technology. We are seeing a move away from traditional glass vials toward pre-filled syringes and ready-to-use cartridges. These “unit-dose” systems reduce the risk of dosing errors and contamination that can occur when a medication must be drawn from a vial in a busy clinical setting. This focus on “point-of-care” safety is a major driver of innovation in the industry.

Furthermore, the rise of biologics injection has introduced new challenges related to stability and viscosity. Many biological drugs are highly concentrated and can become extremely thick, making them difficult to inject through standard needles. Advanced manufacturing techniques are now producing “low-friction” syringes and specialized needles that allow for a smooth and painless delivery even for the most viscous of formulations. Additionally, the use of “continuous manufacturing” processes for injectables is helping to reduce the lead time for critical medications, ensuring that hospitals and clinics have a steady supply of the treatments they need most. This robust manufacturing infrastructure is the invisible foundation upon which modern parenteral therapy is built.

Advancements in Parenteral Delivery and Long-Acting Injectables

One of the most significant breakthroughs in injectable drug delivery systems is the development of long-acting injectables (LAIs). These formulations are designed to release a steady dose of medication over several weeks or even months from a single injection site. This is often achieved through the use of biodegradable microspheres or “in-situ” forming gels that create a drug reservoir under the skin. LAIs have been particularly transformative in the fields of psychiatry and addiction medicine. For patients managing conditions like schizophrenia, the ability to receive a single monthly injection instead of daily pills can be the difference between a stable life and a cycle of relapse. By ensuring consistent therapeutic levels in the blood, LAIs provide a level of stability that oral medications often cannot match.

In addition to chronic disease management, innovations in parenteral delivery are also focusing on the development of “needle-free” injection systems. These devices use high-pressure gas or springs to push a fine stream of liquid medication through the skin’s pores, eliminating the need for a physical needle. This not only reduces the risk of needle-stick injuries for healthcare workers but also addresses the significant issue of needle phobia among patients. As these systems become more affordable and easier to use, they have the potential to democratize access to injectable therapies, making them a viable option even for self-administration in the home.

The Role of Biologics Injection in Modern Oncology

Oncology remains the primary field where injectable drug delivery systems are most critical. Many of the most advanced cancer therapies, such as monoclonal antibodies and immune checkpoint inhibitors, are large proteins that must be delivered parenterally. The focus in this area is on “targeted injectables” formulations that can be delivered directly into a tumor or a specific body cavity to maximize the local effect while minimizing systemic toxicity. For example, intraperitoneal injections are being used to treat ovarian cancers, delivering high concentrations of chemotherapy directly to the site of the disease. This localized approach allows for more aggressive treatment with fewer systemic side effects, significantly improving the patient’s quality of life during therapy.

Furthermore, the integration of “smart” infusion pumps is revolutionizing the way these drugs are administered in clinical settings. These pumps can be programmed with complex dosing schedules and are equipped with safety features that prevent the accidental delivery of an incorrect dose. When combined with real-time monitoring of the patient’s vital signs, these systems create a closed-loop environment where the delivery of the drug is constantly adjusted to the patient’s immediate needs. This level of precision is the hallmark of advanced therapeutics, ensuring that every patient receives the most effective and safest treatment possible.

Future Horizons: Biodegradable Implants and Digital Integration

Looking forward, the future of injectable drug delivery lies in the integration of digital technology and advanced materials science. We are seeing the development of “connected” injectors that can automatically record the time and dose of every injection and send that data directly to a patient’s electronic health record. This allows clinicians to monitor adherence in real-time and provides a wealth of data that can be used to optimize treatment plans. Furthermore, the development of biodegradable “micro-implants” that can be injected through a standard needle and then provide a controlled release of medication for over a year is on the horizon. These devices represent the ultimate in “long-acting” therapy, potentially curing certain conditions with a single intervention.

The sustainability of injectable systems is also a major focus for future innovation. The industry is working to develop more environmentally friendly materials for syringes and packaging, as well as recycling programs for medical devices. By reducing the waste associated with parenteral delivery, we can ensure that these life-saving technologies are as sustainable as they are effective. Through continuous improvement in both the “software” of formulation and the “hardware” of delivery devices, the field of injectable drug delivery is ensuring that the most advanced therapies of the future can be delivered with unparalleled precision, safety, and compassion.

The core premise of personalized drug delivery is that each person’s body interacts with a medication in a slightly different way. Factors such as genetic polymorphisms in liver enzymes, differences in gut microbiome composition, and even daily variations in circadian rhythms can all influence how a drug is absorbed, metabolized, and excreted. By leveraging data from genomic sequencing and real-time health monitoring, clinicians can now design delivery profiles that optimize the therapeutic effect while minimizing the risk of adverse reactions. This precision is not just a luxury; it is a clinical necessity in fields like oncology, where the genetic makeup of a tumor can vary significantly from one patient to another, requiring a highly specific and targeted drug delivery approach.

The Role of Pharma Innovation in Tailored Treatments

The move toward personalized therapeutics is being driven by rapid advancements in diagnostic technology and materials science. We are seeing the development of “companion diagnostics” tests that are performed before a treatment begins to determine which drug and which delivery method will be most effective for a specific patient. This ensuring that the right patient receives the right treatment at the right time, preventing the “trial and error” approach that has long characterized the management of complex chronic diseases. In this context, pharma innovation is not just about creating new molecules, but about creating the systems and intelligence that allow those molecules to be used with maximum efficiency.

One of the most visible examples of this innovation is the use of 3D printing in pharmaceutical manufacturing. 3D printing allows for the creation of “personalized pills” that can combine multiple different medications into a single tablet, each with its own customized release profile. For a patient with a complex regimen, this could mean replacing five different bottles with one tailor-made pill that releases each drug at the exact time of day when it will be most effective. This level of customization was once thought to be an impossible dream, but it is now becoming a reality, offering a powerful tool for improving adherence and reducing the risk of drug-drug interactions.

Precision Medicine and the Power of Targeted Drug Delivery

A critical component of personalized drug delivery is the ability to target the medication to specific cells or tissues. In precision medicine, the goal is often to deliver a potent agent directly to a diseased site such as a tumor or an inflamed joint without exposing the rest of the body to the drug’s toxic effects. This is achieved through the use of functionalized nanoparticles or ligand-targeted carriers that recognize specific molecular markers on the surface of target cells. Because the markers vary from person to person, the delivery system itself must be personalized to match the patient’s unique biological signature.

Furthermore, the concept of “temporal personalization” is gaining traction. This involves timing the delivery of a drug to coincide with the periods of greatest need or the body’s natural peaks in drug metabolism. For example, in the treatment of asthma or rheumatoid arthritis, where symptoms are often worse at night or in the early morning, personalized delivery systems can be designed to release a higher dose during those specific windows. By aligning the medication with the body’s internal clock, we can achieve better symptom control with lower overall doses of medication. This focus on the “when” as much as the “where” is a hallmark of the most advanced personalized therapeutics.

Patient Centric Care and the Integration of Digital Health

At its most fundamental level, personalized drug delivery is about empowering the patient and placing them at the center of their own care. The integration of digital health tools, such as wearable sensors and mobile health apps, allows for the continuous monitoring of a patient’s response to therapy. This real-time data can be used to make immediate adjustments to the drug delivery profile. Imagine a smart insulin pump that not only monitors blood glucose but also learns the patient’s exercise and eating patterns to provide a truly personalized delivery of insulin. This is the essence of patient centric care, where the technology adapts to the human, rather than the human having to adapt to the technology.

This data-driven approach also allows for a more collaborative relationship between the patient and the healthcare provider. Instead of waiting for a monthly check-up to report side effects or treatment failures, the data provides an objective and continuous record of the treatment’s success. This enables “proactive” rather than “reactive” medicine, where potential issues can be identified and corrected before they lead to serious complications. By making the treatment process more transparent and responsive, personalized drug delivery is not just improving health outcomes; it is also improving the overall quality of the healthcare experience.

Future Horizons: From Genomics to Global Accessibility

As we look toward the future, the potential for personalized drug delivery is boundless. The integration of artificial intelligence and machine learning with large-scale genomic data will allow us to predict with incredible accuracy how any given individual will respond to a new therapy. This will accelerate the drug development process and ensure that new treatments are safe and effective from day one. We are also seeing the development of “smart” implants that can be remotely programmed to release medication in response to changing clinical needs, providing a truly autonomous and personalized therapy.

However, the challenge for the future will be ensuring that these advanced personalized therapeutics are accessible to everyone, not just those in the most developed countries. This will require a global effort to reduce the cost of genomic sequencing and to develop scalable manufacturing technologies like 3D printing that can be deployed in diverse settings. The goal is to create a world where personalized care is the standard, not the exception. By continuing to innovate at the intersection of biology and technology, we are building a more equitable and effective healthcare system that recognizes and respects the unique needs of every individual on the planet.